肿瘤灭活自体骨移植在保肢手术中的并发症、功能与生存率:日本肌肉骨骼肿瘤组多中心研究
本研究为回顾性多中心观察性研究,纳入310例接受深冻、巴氏灭活或辐照处理的肿瘤灭活自体骨移植的骨与软组织肿瘤患者,中位随访92个月。结果显示5年与10年任何并发症累积发生率分别为42%和51%,移植骨5年与10年累积生存率分别为87%和81%,中位肌肉骨骼肿瘤学会评分为83%。长切除(≥15 cm)与复合重建增加移植骨移除风险,三种灭活方法在并发症和移植骨生存上无差异。
要点
- 5年与10年任何并发症累积发生率分别为42%和51%,最常见为非连接36例和感染34例。
- 5年与10年移植骨累积生存率分别为87%和81%。
- 长切除(≥15 cm)与复合重建增加移植骨移除风险(RR 2.5与RR 2.3)。
核心结论
- 冷冻、辐照和巴氏灭活的肿瘤灭活自体骨移植具有相似的并发症发生率、移植骨生存率和肢体功能。
- 复发率为10%,但灭活自体骨移植处无肿瘤复发。
- 肿瘤灭活自体骨移植具有合理的生存率和良好的肢体功能,与骨异体移植的报道结果相当。
- 肿瘤灭活自体骨移植是生物重建的有用选择,适用于成骨性或溶骨性肿瘤且无严重机械性骨强度丧失者。
- 当获取异体骨困难或患者因费用或社会宗教原因不愿使用肿瘤假体和异体骨时,可考虑肿瘤灭活自体骨移植。
研究设计与样本
- 回顾性、多中心、观察性研究,纳入日本肌肉骨骼肿瘤组附属的26家三级肉瘤中心的数据。
- 1993年1月至2018年12月,494例长骨良性或恶性肿瘤患者接受了肿瘤灭活自体骨移植(深冻、巴氏灭活或辐照技术)。
- 纳入标准为接受间置或复合(带全关节置换的骨关节自体骨移植)肿瘤灭活自体骨移植并随访至少2年者;最终310例(494例中的63%)纳入分析。
- 中位随访92个月(范围24至348个月),中位年龄27岁(范围4至84岁),女性占48%(310例中的148例);冷冻47%(147例)、巴氏灭活29%(89例)、辐照24%(74例)。
主要发现
- 任何并发症的累积发生率5年为42%,10年为51%;最常见并发症为非连接36例和感染34例。
- 多因素分析显示长切除(≥15 cm)与任何并发症风险增加相关(RR 1.8 [95% CI 1.3至2.5];p < 0.01);三种灭活方法的并发症发生率无差异。
- 移植骨累积生存率5年为87%,10年为81%;控制混杂变量后,长切除(≥15 cm)与复合重建与移植骨移除风险增加相关(RR 2.5 [95% CI 1.4至4.5];p < 0.01 和 RR 2.3 [95% CI 1.3至4.1];p < 0.01)。
- 蒂部冷冻程序显示优于体外灭活程序的移植骨生存(5年94% vs 85%;RR 3.1 [95% CI 1.1至9.0];p = 0.03);三种灭活方法的移植骨生存无差异。
- 间置组78%(200例中的156例)和复合组87%(45例中的39例)在2年内达到一期连接;间置组中男性与非血管化移植与无连接风险增加相关(RR 2.8 [95% CI 1.3至6.1];p < 0.01 和 RR 0.28 [95% CI 0.1至1.0];p = 0.04)。
关键数值与推荐
- 并发症分类和移植失败采用国际保肢学会提出的分类。
- 肢体功能采用肌肉骨骼肿瘤学会评分评估。
临床怎么用
- 肿瘤灭活自体骨移植是生物重建的有用选择,适用于成骨性或溶骨性肿瘤且无严重机械性骨强度丧失者(作者结论)。
- 当获取异体骨困难或患者因费用或社会宗教原因不愿使用肿瘤假体和异体骨时,可考虑肿瘤灭活自体骨移植(作者结论)。
局限性
- 7%(494例中的37例)患者因2年内死亡被排除;19%(96例)使用了骨关节移植,另10%(51例)失访或数据集不完整;未收集死亡或失访者的信息。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tumor-devitalized autografts treated with deep freezing, pasteurization, and irradiation are biological reconstruction methods after tumor excision for aggressive or malignant bone or soft tissue tumors that involve a major long bone. Tumor-devitalized autografts do not require a bone bank, they carry no risk of viral or bacterial disease transmission, they are associated with a smaller immunologic response, and they have a better shape and size match to the site in which they are implanted. However, they are associated with disadvantages as well; it is not possible to assess margins and tumor necrosis, the devitalized bone is not normal and has limited healing potential, and the biomechanical strength is decreased owing to processing and tumor-related bone loss. Because this technique is not used in many countries, there are few reports on the results of this procedure such as complications, graft survival, and limb function. QUESTIONS/PURPOSES: (1) What was the rate of complications such as fracture, nonunion, infection, or recurrence in a tumor-devitalized autograft treated with deep freezing, pasteurization, and irradiation, and what factors were associated with the complication? (2) What were the 5-year and 10-year grafted bone survival (free from graft bone removal) of the three methods used to devitalize a tumor-containing autograft, and what factors were associated with grafted bone survival? (3) What was the proportion of patients with union of the tumor-devitalized autograft and what factors were associated with union of the graft-host bone junction? (4) What was the limb function after the tumor-devitalized autograft, and what factors were related to favorable limb function? METHODS: This was a retrospective, multicenter, observational study that included data from 26 tertiary sarcoma centers affiliated with the Japanese Musculoskeletal Oncology Group. From January 1993 to December 2018, 494 patients with benign or malignant tumors of the long bones were treated with tumor-devitalized autografts (using deep freezing, pasteurization, or irradiation techniques). Patients who were treated with intercalary or composite (an osteoarticular autograft with a total joint arthroplasty) tumor-devitalized autografts and followed for at least 2 years were considered eligible for inclusion. Accordingly, 7% (37 of 494) of the patients were excluded because they died within 2 years; in 19% (96), an osteoarticular graft was used, and another 10% (51) were lost to follow-up or had incomplete datasets. We did not collect information on those who died or were lost to follow-up. Considering this, 63% of the patients (310 of 494) were included in the analysis. The median follow-up was 92 months (range 24 to 348 months), the median age was 27 years (range 4 to 84), and 48% (148 of 310) were female; freezing was performed for 47% (147) of patients, pasteurization for 29% (89), and irradiation for 24% (74). The primary endpoints of this study were the cumulative incidence rate of complications and the cumulative survival of grafted bone, assessed by the Kaplan-Meier method. We used the classification of complications and graft failures proposed by the International Society of Limb Salvage. Factors relating to complications and grafted autograft removal were analyzed. The secondary endpoints were the proportion of bony union and better limb function, evaluated by the Musculoskeletal Tumor Society score. Factors relating to bony union and limb function were also analyzed. Data were investigated in each center by a record review and transferred to Kanazawa University. RESULTS: The cumulative incidence rate of any complication was 42% at 5 years and 51% at 10 years. The most frequent complications were nonunion in 36 patients and infection in 34 patients. Long resection (≥ 15 cm) was associated with an increased risk of any complication based on the multivariate analyses (RR 1.8 [95% CI 1.3 to 2.5]; p < 0.01). There was no difference in the rate of complications among the three devitalizing methods. The cumulative graft survival rates were 87% at 5 years and 81% at 10 years. After controlling for potential confounding variables including sex, resection length, reconstruction type, procedure type, and chemotherapy, we found that long resection (≥ 15 cm) and composite reconstruction were associated with an increased risk of grafted autograft removal (RR 2.5 [95% CI 1.4 to 4.5]; p < 0.01 and RR 2.3 [95% CI 1.3 to 4.1]; p < 0.01). The pedicle freezing procedure showed better graft survival than the extracorporeal devitalizing procedures (94% versus 85% in 5 years; RR 3.1 [95% CI 1.1 to 9.0]; p = 0.03). No difference was observed in graft survival among the three devitalizing methods. Further, 78% (156 of 200 patients) of patients in the intercalary group and 87% (39 of 45 patients) of those in the composite group achieved primary union within 2 years. Male sex and the use of nonvascularized grafts were associated with an increased risk of nonunion (RR 2.8 [95% CI 1.3 to 6.1]; p < 0.01 and 0.28 [95% CI 0.1 to 1.0]; p = 0.04, respectively) in the intercalary group after controlling for confounding variables, including sex, site, chemotherapy, resection length, graft type, operation time, and fixation type. The median Musculoskeletal Tumor Society score was 83% (range 12% to 100%). After controlling for confounding variables including age, site, resection length, event occurrence, and graft removal, age younger than 40 years (RR 2.0 [95% CI 1.1 to 3.7]; p = 0.03), tibia (RR 6.9 [95% CI 2.7 to 17.5]; p < 0.01), femur (RR 4.8 [95% CI 1.9 to 11.7]; p < 0.01), no event (RR 2.2 [95% CI 1.1 to 4.5]; p = 0.03), and no graft removal (RR 2.9 [95% CI 1.2 to 7.3]; p = 0.03) were associated with an increased limb function. The composite graft was associated with decreased limb function (RR 0.4 [95% CI 0.2 to 0.7]; p < 0.01). CONCLUSION: This multicenter study revealed that frozen, irradiated, and pasteurized tumor-bearing autografts had similar rates of complications and graft survival and all resulted in similar limb function. The recurrence rate was 10%; however, no tumor recurred with the devitalized autograft. The pedicle freezing procedure reduces the osteotomy site, which may contribute to better graft survival. Furthermore, tumor-devitalized autografts had reasonable survival and favorable limb function, which are comparable to findings reported for bone allografts. Overall, tumor-devitalized autografts are a useful option for biological reconstruction and are suitable for osteoblastic tumors or osteolytic tumors without severe loss of mechanical bone strength. Tumor-devitalized autografts could be considered when obtaining allografts is difficult and when a patient is unwilling to have a tumor prosthesis and allograft for various reasons such as cost or socioreligious reasons. LEVEL OF EVIDENCE: Level III, therapeutic study.
引用
- Takeuchi A, Tsuchiya H, Setsu N, et al. What Are the Complications, Function, and Survival of Tumor-devitalized Autografts Used in Patients With Limb-sparing Surgery for Bone and Soft Tissue Tumors? A Japanese Musculoskeletal Oncology Group Multi-institutional Study. Clin Orthop Relat Res. 2023. PMID: 37314384. doi:10.1097/CORR.0000000000002720
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。